PromarkerD is being developed to be used as complementary diagnostic (CDx).

The PromarkerD CDx will help physicians better manage their patients by measuring their patient’s response to drug treatment.

The PromarkerD CDx will be valuable in clinical trials of new drugs for diabetic kidney disease by predicting who should be treated, and monitoring which patients respond well or otherwise to a new drug.

If you are interested in using the PromarkerD Complementary Diagnostic in your clinical trial for diabetic kidney disease, please contact us for more information.